NEW YORK, June 17, 2016 /PRNewswire/ -- CBL &
Associates Properties, Inc. (CBL)
Lifshitz & Miller
announces investigation into possible breaches of fiduciary duties
by the CBL board. Specifically, on May
24, 2016, the Wall Street Journal reported
investigations concerning CBL officials falsifying information on
financial statements to banks when applying for financial
arrangements.
For more information about our investigation, please complete
the Information Request Form or contact Joshua Lifshitz, Esq. by
telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Eagle Pharmaceuticals, Inc. (EGRX)
Lifshitz &
Miller announces investigation on behalf of EGRX
investors. Specifically, on March 18,
2016, EGRX announced receipt of a CRL from the FDA,
regarding Kangio, disapproving the drug application in its current
form and requested additional information regarding the substance
used in Kangio.
For more information about our investigation, please complete
the Information Request Form or contact Joshua Lifshitz, Esq. by
telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
HCP, Inc. (HCP)
Lifshitz & Miller announces
investigation on behalf of HCP investors. Specifically, on
February 9, 2016, HCP disclosed that
its equity stake in ManorCare had been written down to zero, and
that it had taken an $836 million
non-cash impairment on its ManorCare lease assets and placed all of
its ManorCare real estate assets on a "Watch List."
For more information about our investigation, please complete
the Information Request Form or contact Joshua Lifshitz, Esq. by
telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Immunomedics, Inc. (IMMU)
Lifshitz & Miller
announces investigation into possible breaches of fiduciary duties
by Immunomedics board. Specifically, the investigation
relates to whether Immunomedics misrepresented to
ASCO that its abstract for IMMU-132
contained only updated and previously undisclosed data in
violation of ASCO's policy.
For more information about our investigation, please complete
the Information Request Form or contact Joshua Lifshitz, Esq. by
telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Infinity Pharmaceuticals Inc. (INFI)
Lifshitz &
Miller announces investigation into possible breaches of fiduciary
duties by the INFI board. Specifically, on June 14, 2016, INFI announced a restructuring
that would reduce its workforce by 21% in the wake of disappointing
drug-study results.
For more information about our investigation, please complete
the Information Request Form or contact Joshua Lifshitz, Esq. by
telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Neovasc, Inc. (NVCN)
Lifshitz & Miller announces
investigation on behalf of Neovasc investors. Specifically,
the investigation will focus on multiple media reports that claim a
Massachusetts federal jury awarded
a $70 million verdict to Neovasc's
rival, CardiAQ Valve Technologies Inc. ("CardiAQ"), finding that
Neovasc had stolen trade secrets from CardiAQ.
For more information about our investigation, please complete
the Information Request Form or contact Joshua Lifshitz, Esq. by
telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Unilife Corporation (UNIS)
Lifshitz & Miller
announces investigation into possible breaches of fiduciary duties
by UNIS board. Specifically, the investigation relates to
whether Unilife's former CEO and its former Chairman had violated
Company policies and broken laws and regulations; and Unilife
lacked sufficient accounting and financial reporting internal
controls.
For more information about our investigation, please complete
the Information Request Form or contact Joshua Lifshitz, Esq. by
telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
ATTORNEY ADVERTISING. © 2016 Lifshitz &
Miller. The law firm responsible for this advertisement is
Lifshitz & Miller, 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel:
(516)493-9780. Prior results do not guarantee or predict a
similar outcome with respect to any future matter.
Contact:
Joshua M.
Lifshitz, Esq.
Lifshitz & Miller
Phone: 516-493-9780
Facsimile: 516-280-7376
Email:
info@jlclasslaw.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lifshitz--miller-law-firm-announces-investigation-of-cbl--associates-properties-inc-eagle-pharmaceuticals-inc-hcp-inc-immunomedics-inc-infinity-pharmaceuticals-inc-neovasc-inc-and-unilife-corporation-300286669.html
SOURCE Lifshitz & Miller Law Firm